ArticleCancer discovery2022
Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells.
Abstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Targeting CDKs in the RNAPII transcription cycle.Nature reviews. Drug discovery · 2026Review
- NAT10-dependent NCell reports · 2026Article
- IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2.Nature communications · 2026Article
- CDK12/CDK13 inhibition disrupts transcriptional elongation and replication fork progression in glioblastoma.EMBO molecular medicine · 2026Article
- Prognostic relevance and cytokine correlates of peripheral immune subpopulations in newly diagnosed glioblastoma.Journal of neuro-oncology · 2026Article
- Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis.Biologics : targets & therapy · 2026Review
- Defining treatment-resistant brain cancer: Genetic screening to identify oncogene-driven immunomodulation and therapy resistance.Cancer gene therapy · 2026Review
- SUV39H2 is a vulnerability in glioblastoma stem cells enhanced by co-targeting SUV39H1.Epigenomics · 2025Article
- Biology of stem cell paradox: a double-edged sword-implications for cancer therapy.Cancer cell international · 2025Review
- Targeting Transcriptional Cyclin-Dependent Kinases in Cancer.Molecular cancer therapeutics · 2025Review
- Profiling with senescence-associated secretory phenotype score identifies GDC-0879 as a small molecule sensitizing glioblastoma to anti-PD1.Cell death & disease · 2025Article
- Enhancer regulation in cancer: from epigenetics to mArchives of pharmacal research · 2025Review
- Yin Yang 1 (YY1) as a Central Node in Drug Resistance Pathways: Potential for Combination Strategies in Cancer Therapy.Biomolecules · 2025Review
- Pan-cancer analysis and experimental validation revealed the prognostic role of ZNF83 in renal and lung cancer cohorts.Discover oncology · 2025Article
- Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review.International journal of molecular sciences · 2025Article
- RNA mCell investigation · 2025Article
- USP18 deubiquitinates and stabilizes SOX9 to promote the stemness and malignant progression of glioblastoma.Cell death discovery · 2025Article
- Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.Journal of neuro-oncology · 2025Review
- RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond.Experimental hematology & oncology · 2025Review
- Regulation and application of mScience China. Life sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Zhixin Qiu *Hillman Cancer Center and Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0001-7103-8004
Linjie Zhao *Hillman Cancer Center and Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Jia Z Shen *Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.ORCID 0000-0002-4983-2049
Zhengyu LiangDepartment of Cellular and Molecular Medicine, Institute of Genomic Medicine, University of California, San Diego, La Jolla, California.
Qiulian WuHillman Cancer Center and Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Kailin YangDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0001-5968-6738
Lihua MinHillman Cancer Center and Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Ryan C GimpleDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-7189-3243
Qiyuan YangNOMIS Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, California.
Shruti BhargavaDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Chunyu JinHoward Hughes Medical Institute, Department of Medicine, University of California, San Diego, La Jolla, California.
Cheryl KimFlow Cytometry Core Facility, La Jolla Institute for Immunology, La Jolla, California.ORCID 0000-0001-9535-5709
Denise HinzFlow Cytometry Core Facility, La Jolla Institute for Immunology, La Jolla, California.
Deobrat DixitDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Jean A BernatchezCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California.ORCID 0000-0002-8309-1627
Briana C PragerDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Guoxin ZhangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Zhen DongDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Deguan LvHillman Cancer Center and Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0003-3142-9814
Xujun WangSJTU-Yale Joint Center for Biostatistics, School of Life Science and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Leo J Y KimDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Zhe ZhuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-5385-948X
Katherine A JonesRegulatory Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California.
Ye ZhengNOMIS Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, California.
Xiuxing WangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-5993-9368
Jair L Siqueira-NetoCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California.
Lukas ChavezDepartment of Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-8718-8848
Xiang-Dong FuDepartment of Cellular and Molecular Medicine, Institute of Genomic Medicine, University of California, San Diego, La Jolla, California.
Charles SpruckTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California. drjeremyrich@gmail.com cspruck@sbpdiscovery.org.ORCID 0000-0003-0453-6796
Jeremy N RichHillman Cancer Center and Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. drjeremyrich@gmail.com cspruck@sbpdiscovery.org.
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MTumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MDynamic Complexity of Brain Tumor Stem Cells (R35CA197718)R35CA197718 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2015 to 2021
$6.4MTreg development and function controlled by cis-regulatory circuitsR01AI107027 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI ZHENG, YE · 2014 to 2022
$5.0MThe role of BAF related complexes in regulatory T cell development and functionR01AI151123 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI HARGREAVES, DIANA CLARE, ZHENG, YE · 2020 to 2024
$4.0MTargeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)R01CA238662 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAY, STEVE A, RICH, JEREMY N · 2020 to 2024
$2.8MComputational Genomic Epidemiology of Cancer (CoGEC) Training ProgramT32CA094186 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Thomas Louis LaFramboise, Rong Xu · 2017 to 2026
$2.6MDual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434)R01NS103434 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2017 to 2021
$1.7MCyTOF Mass CytometerS10OD018499 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P · 2014 to 2014
$802kThe Unfolded Protein Response in GlioblastomaF30CA217066 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI PRAGER, BRIANA · 2017 to 2020
$195kNCI NIH HHS F30 CA217065NCI NIH HHS F30 CA217066NCI NIH HHS P30 CA014195NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA238662NCI NIH HHS R35 CA197718NCI NIH HHS T32 CA094186NIAID NIH HHS R01 AI107027NIAID NIH HHS R01 AI151123NIGMS NIH HHS T32 GM007250NIH HHS S10 OD018499NINDS NIH HHS R01 NS103434
Abstract
Glioblastoma (GBM) is the most lethal primary brain cancer characterized by therapeutic resistance, which is promoted by GBM stem cells (GSC). Here, we interrogated gene expression and whole-genome CRISPR/Cas9 screening in a large panel of patient-derived GSCs, differentiated GBM cells (DGC), and neural stem cells (NSC) to identify master regulators of GSC stemness, revealing an essential transcription state with increased RNA polymerase II-mediated transcription. The YY1 and transcriptional CDK9 complex was essential for GSC survival and maintenance
Indexed as
ImmunotherapyAnimalsBrain NeoplasmsEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticGlioblastomaHumansMaleMiceMiddle AgedNeoplastic Stem CellsTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.